OTCMKTS:KYKOF Kyowa Kirin 5/7/2026 Earnings Report $15.05 0.00 (0.00%) As of 05/1/2026 ProfileForecast Kyowa Kirin EPS ResultsActual EPSN/AConsensus EPS $0.17Beat/MissN/AOne Year Ago EPSN/AKyowa Kirin Revenue ResultsActual RevenueN/AExpected Revenue$758.31 millionBeat/MissN/AYoY Revenue GrowthN/AKyowa Kirin Announcement DetailsQuarterDate5/7/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile Kyowa Kirin Earnings HeadlinesKyowa Kirin stops development of skin condition treatmentMarch 3, 2026 | reuters.comKyowa Kirin announces management changesDecember 11, 2025 | msn.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain ChairmanDecember 11, 2025 | businesswire.comKyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual MeetingNovember 18, 2025 | globenewswire.comKyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the RegionNovember 3, 2025 | businesswire.comSee More Kyowa Kirin Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kyowa Kirin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyowa Kirin and other key companies, straight to your email. Email Address About Kyowa KirinKyowa Kirin (OTCMKTS:KYKOF) Co., Ltd. is a global biopharmaceutical company headquartered in Tokyo, Japan, specializing in the research, development and commercialization of innovative therapies. Established through the merger of Kyowa Hakko Kogyo Co., Ltd. and Kirin Pharma Co., Ltd. in 2008, the company operates as part of the Kirin Group and pursues a mission of delivering cutting-edge medicines in areas of high unmet medical need. Its corporate structure supports integrated research and development, manufacturing and worldwide licensing activities. The company’s therapeutic focus spans oncology, nephrology, immunology and central nervous system disorders. Kyowa Kirin markets a range of antibody-based drugs and small-molecule therapies, including treatments for rare genetic and autoimmune conditions. Its pipeline features next-generation biologics, antibody-drug conjugates and cell therapies in various stages of clinical development. In addition to in-house projects, the company leverages strategic collaborations and licensing agreements to expand its product offerings and accelerate access to novel treatment modalities. Kyowa Kirin distributes its products globally, with a strong presence in Japan, North America, Europe and Asia Pacific. It maintains research facilities and manufacturing sites in multiple regions to support clinical trials and commercial supply. The company’s management team, overseen by a President and CEO and supported by an experienced board of directors, is committed to advancing patient-centric innovation and fostering sustainable growth across its international footprint.View Kyowa Kirin ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
